IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9708286 B1

PDFFull Text
Date of Patent:
Jul. 18, 2017

Filed:

Jun. 24, 2015

Ingenol-3-acylates iii and ingenol-3-carbamates

Applicant:

Leo Laboratories Limited, Dublin, IE;

Inventors:

Gunnar Grue-Sørensen, Ballerup, DK;

Xifu Liang, Ballerup, DK;

Thomas Högberg, Ballerup, DK;

Kristoffer Månsson, Ballerup, DK;

Per Vedsø, Ballerup, DK;

Thomas Vifian, Ballerup, DK;

Assignee:

LEO LABORATORIES LIMITED, Dublin, IE;

Attorney:

Birch, Stewart, Kolasch & Birch, LLP

Primary Examiner:

Savitha Rao

Assistant Examiner:

Angela Brown-Pettigrew

Int. Cl.
CPC ...
C07C 271/34 (2006.01); C07D 333/38 (2006.01); C07C 271/36 (2006.01); C07C 271/38 (2006.01); C07D 249/06 (2006.01); C07D 261/18 (2006.01); C07D 277/32 (2006.01); C07D 295/21 (2006.01); C07D 309/08 (2006.01); C07D 401/04 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01); C07D 265/36 (2006.01); C07D 271/08 (2006.01); C07D 277/587 (2006.01); C07D 295/205 (2006.01); C07D 307/00 (2006.01); C07D 307/94 (2006.01); C07D 405/06 (2006.01); C07D 513/04 (2006.01); A61K 31/365 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/415 (2006.01); A61K 31/416 (2006.01); A61K 31/4192 (2006.01); A61K 31/42 (2006.01); A61K 31/472 (2006.01); A61K 31/502 (2006.01); A61K 31/5375 (2006.01); A61K 31/538 (2006.01); C07D 209/42 (2006.01); C07D 217/26 (2006.01); C07D 231/14 (2006.01); C07D 231/56 (2006.01); C07D 237/28 (2006.01); C07D 249/04 (2006.01);
U.S. Cl.
CPC ...
C07D 333/38 (2013.01); A61K 31/365 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4192 (2013.01); A61K 31/42 (2013.01); A61K 31/472 (2013.01); A61K 31/502 (2013.01); A61K 31/538 (2013.01); A61K 31/5375 (2013.01); C07C 271/34 (2013.01); C07C 271/36 (2013.01); C07C 271/38 (2013.01); C07D 209/42 (2013.01); C07D 217/26 (2013.01); C07D 231/14 (2013.01); C07D 231/56 (2013.01); C07D 237/28 (2013.01); C07D 249/04 (2013.01); C07D 249/06 (2013.01); C07D 261/18 (2013.01); C07D 265/36 (2013.01); C07D 271/08 (2013.01); C07D 277/32 (2013.01); C07D 277/587 (2013.01); C07D 295/205 (2013.01); C07D 295/21 (2013.01); C07D 307/00 (2013.01); C07D 307/94 (2013.01); C07D 309/08 (2013.01); C07D 401/04 (2013.01); C07D 405/06 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); C07C 2103/86 (2013.01);
Abstract

The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

Find Patent Forward Citations

Loading…